Canaccord Genuity reiterated their buy rating on shares of Sientra (NASDAQ:SIEN) in a research note published on Friday, January 5th. Canaccord Genuity currently has a $19.00 price target on the medical instruments supplier’s stock.
Several other equities analysts have also issued reports on the stock. Zacks Investment Research raised shares of Sientra from a sell rating to a hold rating in a report on Tuesday, January 2nd. ValuEngine upgraded shares of Sientra from a sell rating to a hold rating in a research note on Sunday, December 31st. BidaskClub upgraded shares of Sientra from a sell rating to a hold rating in a research note on Friday, December 15th. Stifel Nicolaus reiterated a hold rating and set a $14.00 price objective (up from $11.00) on shares of Sientra in a research note on Wednesday, September 27th. Finally, William Blair upgraded shares of Sientra from a market perform rating to an outperform rating in a research note on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $15.00.
Shares of Sientra (NASDAQ:SIEN) traded down $0.63 during mid-day trading on Friday, reaching $12.52. 219,900 shares of the company traded hands, compared to its average volume of 169,288. The stock has a market capitalization of $242.83, a price-to-earnings ratio of -4.39 and a beta of -1.47. The company has a current ratio of 2.87, a quick ratio of 1.92 and a debt-to-equity ratio of 0.57. Sientra has a 12 month low of $7.20 and a 12 month high of $16.68.
Sientra (NASDAQ:SIEN) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.06). Sientra had a negative return on equity of 68.82% and a negative net margin of 169.77%. The firm had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $10.54 million. During the same period in the prior year, the firm posted ($0.55) earnings per share. Sientra’s revenue for the quarter was up 50.8% compared to the same quarter last year. analysts anticipate that Sientra will post -3.23 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of SIEN. Morgan Stanley lifted its position in Sientra by 449.6% during the first quarter. Morgan Stanley now owns 128,358 shares of the medical instruments supplier’s stock valued at $1,081,000 after purchasing an additional 105,005 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in Sientra during the second quarter valued at $252,000. Rhumbline Advisers acquired a new position in shares of Sientra in the second quarter worth about $158,000. Bank of New York Mellon Corp raised its position in shares of Sientra by 74.4% in the second quarter. Bank of New York Mellon Corp now owns 90,274 shares of the medical instruments supplier’s stock worth $877,000 after acquiring an additional 38,514 shares during the period. Finally, Neuberger Berman Group LLC acquired a new position in shares of Sientra in the second quarter worth about $292,000. Institutional investors own 76.63% of the company’s stock.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.